CASE REPORT

Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer

Kana Kubota,1 Taro Shinozaki,2 Yasushi Imai,1,3 Kazuomi Kario1

SUMMARY

Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare complication of cancer, which can be lethal due to progressive pulmonary hypertension (PH). Several case reports have demonstrated that imatinib, a platelet-derived growth factor receptor–tyrosine kinase inhibitor, can improve severe PH in patients with PTTM. We describe the case of a 56-year-old woman. Her mean pulmonary arterial pressure (mPAP) was 47 mm Hg, and her dyspnoea worsened rapidly over several days. Although pulmonary embolism was not observed on CT, enlargement of the para-aortic lymph nodes was detected. Gastro-oesophageal endoscopy revealed signet-ring cell carcinoma. We diagnosed her as having PTTM based on her clinical course, and started treatment with imatinib. Five days after its administration, her mPAP decreased dramatically. She was discharged and lived without symptoms of PH until her death due to systemic metastasis of carcinoma. In some cases of PTTM, imatinib may be an effective therapeutic option for PH.

BACKGROUND

Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare but fatal pulmonary complication of cancer, which was first described by von Herbay et al. The clinical presentation typically is acute dyspnoea, followed by a very rapid clinical course, progressing to death in a matter of hours to days.1 In fact, it has been reported that only 7 of 103 patients were pathologically diagnosed with PTTM while still alive.2 Platelet-derived growth factor (PDGF) stimulation has been reported to be involved in the proliferation and anti-apoptosis of pulmonary artery endothelial cells and smooth muscle cells in patients with pulmonary hypertension (PH).3–5 PDGF is also involved in the progression of PTTM.6 Several case reports from Japan have demonstrated that imatinib, a PDGF receptor–tyrosine kinase inhibitor, can improve severe PH in patients with PTTM. Here, we report a case of PTTM that was alleviated dramatically with imatinib therapy.

CASE PRESENTATION

A 56-year-old woman had a 2-month history of oedema and exertional dyspnoea (WHO functional class II). She had no prior diseases or relevant family history. She was admitted to a nearby hospital where she was found to have severe PH. Figure 1 shows CT; it showed no thrombus in the pulmonary artery as well as no parenchymal lesion such as malignant tumour, lymphangitis carcinomatosa or interstitial...
pneumonia. However, enlargement of the para-aortic lymph nodes was found.

INVESTIGATIONS
Right heart catheterisation showed significant PH (mean pulmonary arterial pressure (mPAP), 47 mm Hg). In Japan, the probability of Helicobacter pylori infection is high; it is known that gastric cancer is much more frequent than in Western countries. In this case, enlargement of the para-aortic lymph nodes was recognised, so we performed gastro-oesophageal endoscopy at an early stage. Gastric cancer was detected, pathologically diagnosed as poorly differentiated adenocarcinoma involving the signet-ring cells.

TREATMENT
Figure 2 shows the clinical course, with PAP measured directly with a Swan-Ganz catheter indwelling from the right internal jugular vein. We started sequential oxygen, dobutamine and bosentan, but there was no improvement in her haemodynamics. Her respiratory condition deteriorated rapidly, and we diagnosed her as having PTTM based on her clinical course. After consulting Dr Hatano from The University of Tokyo, who reported a similar case of PTTM, we started treatment with imatinib (200 mg once daily) on day 10. Because imatinib therapy was off-label, we obtained urgent approval from the institutional ethics committee and received written informed consent from the patient.

OUTCOME AND FOLLOW-UP
After administration of 200 mg imatinib, her PAP decreased dramatically. Five days later, her haemodynamics normalised (mPAP, 12 mm Hg) and her dyspnoea disappeared. Figure 3 shows her echocardiograms before and after imatinib administration. Although mild pericardial effusion remained, the prominent right heart dilatation showed obvious improvement.

She was discharged and periodically visited our hospital for chemotherapy including titanium silicate-1 and oxaliplatin. She did not experience recurrence of PH, and died from systemic metastasis of carcinoma 7 months later.

DISCUSSION
In our case, imatinib remarkably improved acute right heart failure due to PTTM associated with signet-ring cell carcinoma.

Imatinib is a tyrosine kinase inhibitor approved as an anticancer drug for chronic myelogenous leukaemia, Philadelphia chromosome-positive acute lymphoid leukaemia, KIT antibody-positive gastrointestinal stromal tumour and idiopathic hypereosinophilic syndrome. Imatinib inhibits phosphorylation of the BCR-ABL fusion protein, c-KIT protein and PDGF receptor, subsequently blocking many intracellular downstream signalling pathways. Dasatinib, another tyrosine kinase inhibitor, has recently been drawing attention as a cause of drug-induced pulmonary arterial hypertension (PAH), whereas imatinib has...
been reported to be effective in patients with PAH in a recent randomised study (IMPRES study). However, serious adverse events and study drug discontinuations were common. PTTM is thought to occur by obstruction of the pulmonary arterioles by microembolisms of tumour cells, thrombus formation induced by activation of thrombogenic cascades on the surface of tumour embolisms and abnormal proliferation of vascular cells caused by growth factors, such as PDGF and vascular endothelial growth factor, which are induced by tumours. In 2013, Ogawa et al reported the first case of PTTM with severe PH treated successfully with imatinib. However, few cases of PTTM treated with imatinib have been reported in Japan. We summarise the previous literature and our case in Table 1. In this table, in patient 3, total gastrectomy was performed for mass reduction of the tumour, after which the patient’s mPAP decreased from 33 to 13 mm Hg. We also considered gastrectomy in our case, but the tumour mainly involved the para-aortic lymph nodes rather than the stomach itself. Therefore, we did not perform surgery, and it is noteworthy that her PAP improved promptly after administration of imatinib alone.

Imatinib can be particularly effective in patients with PTTM associated with signet-ring cell carcinoma. Fujishiro et al reported 103 patients with PTTM, among whom the most frequent primary cancer was gastric (58 cases), followed by lung (10 cases), breast (7 cases), cancer of unknown primary (15 cases), ovarian (5 cases) and bladder (4 cases). As shown in Table 1, imatinib was effective in three cases of signet-ring cell carcinoma, including our case, but was weaker in cases of colon (patient 2) and breast (patients 4 and 5) cancer. The mechanism is still unclear, but it has been suggested that production of growth factors, including PDGF, might be different depending on the tumour characteristics.

The limitation of this report is that there are few cases of PTTM treated with imatinib, which has not been adopted for PH. This is because PTTM progresses quickly and patients often die before drug administration. Therefore, further accumulation of cases is necessary.

In some cases, imatinib remarkably improves acute right heart failure caused by PTTM. Furthermore, imatinib can be highly effective in cases of PTTM caused by gastric adenocarcinoma, especially signet-ring cell carcinoma. Because patients with PTTM deteriorate rapidly, treatment with imatinib should be considered immediately.

Table 1  Summary of cases with PTTM treated with imatinib

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6 (our case)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset, y</td>
<td>47</td>
<td>61</td>
<td>64</td>
<td>61</td>
<td>45</td>
</tr>
<tr>
<td>Sex</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>Author</td>
<td>Ogawa A</td>
<td>Higo K</td>
<td>Minatsuki S</td>
<td>Fukuda I</td>
<td>Fukuda I</td>
</tr>
<tr>
<td>Primary disease</td>
<td>Gastric adenocarcinoma (signet-ring cells)</td>
<td>Colorectal cancer</td>
<td>Gastric adenocarcinoma (signet-ring cells)</td>
<td>Breast cancer</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Drugs administered</td>
<td>Imatinib 100 mg</td>
<td>Bosentan 90.75 mg epoprostenol 27 ng/kg/min</td>
<td>Imatinib 50–200 mg</td>
<td>Bosentan tadalafil 40 mg</td>
<td>Imatinib 200–400 mg</td>
</tr>
<tr>
<td>Mean PAP after administration of imatinib</td>
<td>47–25 mm Hg</td>
<td>48–35 mm Hg</td>
<td>48–33 mm Hg</td>
<td>60–56 mm Hg</td>
<td>27–30 mm Hg</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>TS-1 40 mg</td>
<td>Bevacizumab 5 mg/kg TS-1 100 mg</td>
<td>TS-1</td>
<td>Eribulin</td>
<td>Capcitabine</td>
</tr>
<tr>
<td>Surgical therapy</td>
<td>(-)</td>
<td>(-)</td>
<td>Total gastrectomy</td>
<td>(-)</td>
<td>(-)</td>
</tr>
<tr>
<td>Survival time</td>
<td>9 months</td>
<td>12 months</td>
<td>12 months</td>
<td>54 days</td>
<td>24 days</td>
</tr>
<tr>
<td>Cause of death</td>
<td>Metastasis</td>
<td>Infection</td>
<td>Metastasis</td>
<td>Respiratory failure</td>
<td>Respiratory failure</td>
</tr>
</tbody>
</table>

PAP, pulmonary arterial pressure; PTTM, pulmonary tumour thrombotic microangiopathy; TS, titanium silicate.

Learning points

- Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare haemodynamic complication of cancer, which can be lethal due to rapid progression of right heart failure caused by pulmonary hypertension.
- In some cases, imatinib remarkably improves acute right heart failure caused by PTTM.
- Because patients with PTTM deteriorate rapidly, treatment with imatinib should be considered immediately.

Contributors  KK and TS were physicians in charge and wrote the manuscript. YI gave precise advice on medical treatment and refined the manuscript. KK supervised the aforementioned staffs and had responsibility for this case report.

Competing interests  None declared.

Patient consent  Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Ethics approval  Because imatinib therapy was off-label, we obtained urgent approval from the institutional ethics committee and received written informed consent from the patient for therapy itself as well as publication. The consent form written in Japanese is attached as PDF files.

Provenance and peer review  Not commissioned; externally peer reviewed.

Open Access  This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

Rare disease


Copyright 2017 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow.